Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF.

Am J Gastroenterol. 2012 Jul;107(7):1051-63. doi: 10.1038/ajg.2012.89. Epub 2012 May 22.

2.

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.

Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.

Aliment Pharmacol Ther. 2009 Aug;30(3):253-64. doi: 10.1111/j.1365-2036.2009.04037.x. Epub 2009 May 6.

3.

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.

Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931.

PMID:
16678077
4.

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.

Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ.

Aliment Pharmacol Ther. 2009 Aug;30(3):210-26. doi: 10.1111/j.1365-2036.2009.04027.x. Epub 2009 Apr 21.

5.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.

6.

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD.

Gastroenterology. 2014 Apr;146(4):941-9. doi: 10.1053/j.gastro.2013.12.025. Epub 2013 Dec 18.

PMID:
24361468
7.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
8.

Safety of infliximab in 10 years of clinical practice.

O'Donnell S, Murphy S, Anwar MM, O'Sullivan M, Breslin N, O'Connor HJ, Ryan BM, O'Morain CA.

Eur J Gastroenterol Hepatol. 2011 Jul;23(7):603-6. doi: 10.1097/MEG.0b013e3283479125.

PMID:
21602689
9.

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J.

Gut. 2010 Oct;59(10):1363-8. doi: 10.1136/gut.2010.212712. Epub 2010 Jun 29.

PMID:
20587545
10.

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R.

Gut. 2004 Jun;53(6):849-53.

11.

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

Abraham NS, Richardson P, Castillo D, Kane SV.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1281-7. doi: 10.1016/j.cgh.2013.06.004. Epub 2013 Jun 19.

PMID:
23792295
12.

Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.

Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO).

Clin Gastroenterol Hepatol. 2009 Sep;7(9):981-7. doi: 10.1016/j.cgh.2009.05.031. Epub 2009 Jun 10.

PMID:
19523534
13.

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2014 Feb;109(2):212-23. doi: 10.1038/ajg.2013.441. Epub 2014 Jan 7.

PMID:
24394749
14.

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM.

J Drugs Dermatol. 2008 Dec;7(12):1137-46.

PMID:
19137767
15.

Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA.

Gastroenterology. 2013 Nov;145(5):1007-1015.e3. doi: 10.1053/j.gastro.2013.07.035. Epub 2013 Jul 25.

PMID:
23891975
16.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.

Clin Ther. 2011 Jul;33(7):946-64. doi: 10.1016/j.clinthera.2011.06.002. Epub 2011 Jul 7.

PMID:
21741088
17.

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.

Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA.

Aliment Pharmacol Ther. 2010 Mar;31(5):553-60. doi: 10.1111/j.1365-2036.2009.04206.x. Epub 2009 Nov 30.

18.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
19.

Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.

Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ.

Am J Gastroenterol. 2004 May;99(5):878-83.

PMID:
15128354
20.

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.

Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M.

Gastroenterology. 2017 Jun;152(8):1901-1914.e3. doi: 10.1053/j.gastro.2017.02.004. Epub 2017 Feb 11.

PMID:
28193515

Supplemental Content

Support Center